Changkang Granule
Phase 3Small molecule
Tasly Pharmaceutical Group Co., LtdChangkang Granule is one of 36 small molecule programs targeting Irritable Bowel Syndrome. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Linzess
AbbVieApproved
Resotran
TakedaApproved
Cymbalta
Jazz PharmaceuticalsApproved
Lexapro
AbbVieApproved
Golytely
BayerApproved
Azulfidine
PfizerApproved
Nurtec
PfizerApproved
Alinia
RRomark Laboratories L.C.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
VIOKACE
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Changkang Granule. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details